Orionis Biosciences

Orionis Biosciences is a private, clinical-stage biotech founded in 2015, focused on creating next-generation cancer therapies through its three core technology platforms: Allo-Glue™ for molecular glues, A-Kine® for conditionally active cytokines, and multimodal cell engagers (MCEs). The company has advanced two A-Kine® candidates, ORB-011 and ORB-021, into Phase 1 clinical trials for solid tumors and has secured significant strategic partnerships with industry leaders like Genentech and Novartis. Orionis operates as a platform/therapeutics company, currently in a pre-revenue stage, with a strategy centered on advancing its internal pipeline while leveraging collaborations to expand the application of its disruptive technologies.

Proprietary platforms include: 1) Allo-Glue™ for small molecule molecular glues that induce protein-protein interactions; 2) A-Kine® for conditionally active cytokine biologics activated only upon binding to target cells; 3) Multimodal Cell Engagers (MCEs) for biologics that connect immune effector cells to target cells.

Orionis competes in the targeted cytokine space with companies like Synthekine, Senti Bio, and Werewolf Therapeutics, and in the molecular glue/degrader field with pioneers like Nurix Therapeutics and Monte Rosa Therapeutics, as well as large pharma. Its differentiation lies in its modular, multi-platform approach to creating conditional connections, but it must demonstrate clinical superiority to capture market share.